Abstract
Th17 and Th1 play an important role in multiple sclerosis for which copolymer I (COP-I) is a treatment option. We described here that the treatment effect of COP-I correlated with its unique regulatory properties on differentiation and survival of Th17 in experimental autoimmune encephalomyelitis mice, which was mediated through down-regulation of STAT3 phosphorylation. The effect of COP-I on Th17 differentiation required CD14+ monocytes through IL-6 signaling as a key mediator to regulate STAT3 phosphorylation and subsequent RORγt expression in Th17 cells. The observed effect was markedly dampened when monocytes were genetically deficient for IL-6. Similar regulatory properties of COP-I were demonstrated in human Th17 differentiation. The study revealed the differential regulatory roles and the novel mechanism of action of COP-I chiefly responsible for its treatment efficacy in experimental autoimmune encephalomyelitis and multiple sclerosis.
Cite
CITATION STYLE
Chen, C., Liu, X., Wan, B., & Zhang, J. Z. (2009). Regulatory Properties of Copolymer I in Th17 Differentiation by Altering STAT3 Phosphorylation. The Journal of Immunology, 183(1), 246–253. https://doi.org/10.4049/jimmunol.0900193
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.